PD
BTAI icon

Point72 (DIFC)’s BioXcel Therapeutics BTAI Stock Holding History

Point72 (DIFC)’s Portfolio BTAI Stock Details BTAI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q1 		– Sell
-2
Closed -$13 – 1691
2024
Q4 		$13 Hold
2
– – ﹤0.01% 1467
2024
Q3 		$19 Sell
2
-961
-100% -$12.9K ﹤0.01% 1383
2024
Q2 		$19.7K Buy
+963
New +$32.2K ﹤0.01% 1238

Other funds holding BTAI

M
Murchinson Toronto, Ontario, Canada $791M AUM 68.08% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
BPA
Beacon Pointe Advisors Newport Beach, California $18.9B AUM 18.9% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Wells Fargo
Wells Fargo San Francisco, California $530B AUM 22.01% 1-Year Est. Return
VF
Virtu Financial New York $2.41B AUM 48.35% 1-Year Est. Return
Barclays
Barclays London, United Kingdom $416B AUM 33.63% 1-Year Est. Return

Point72 (DIFC)'s BTAI Position: Q1 2025 in Review

Point72 (DIFC) sold out of BioXcel Therapeutics (BTAI) in Q1 2025, closing a stake of 2 shares — an estimated $13 sold.

Point72 (DIFC) first reported a position in BTAI in Q2 2024 and held it in 3 quarters. The position peaked at $19.7K in Q2 2024. 31 funds tracked by Wall St. Rank hold BTAI as of Q1 2025.

  • Point72 (DIFC) reported no remaining BioXcel Therapeutics position as of Q1 2025 after selling out during the quarter.
  • Point72 (DIFC) sold 2 BioXcel Therapeutics shares in Q1 2025, an estimated $13.
  • Point72 (DIFC) first reported a position in BioXcel Therapeutics in Q2 2024 and held it in 3 quarters.
  • Point72 (DIFC)'s BioXcel Therapeutics position peaked at $19.7K in Q2 2024.
  • 31 funds tracked by Wall St. Rank held BioXcel Therapeutics as of Q1 2025.

Based on Point72 (DIFC)'s 13F filing for Q1 2025, filed 15 May 2025.